New guinea pig model of Cryptococcal meningitis.
We developed a guinea pig model of cryptococcal meningitis to evaluate antifungal agents. Immunosuppressed animals challenged intracranially with Cryptococcus neoformans responded to fluconazole and voriconazole. Disease was monitored by serial cerebrospinal fluid (CSF) cultures and quantitative organ cultures. Our model produces disseminating central nervous system disease and responds to antifungal therapy.
Kirkpatrick
William R
WR
The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Infectious Diseases, San Antonio, TX 78229-3900, USA. kirkpatrick@uthscsa.edu
Najvar
Laura K
LK
Bocanegra
Rosie
R
Patterson
Thomas F
TF
Graybill
John R
JR
D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000382:microbiology; D015169:Colony Count, Microbial; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D004195:Disease Models, Animal; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D016919:Meningitis, Cryptococcal / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D015725:Fluconazole; D065819:Voriconazole